Inverse relationship between LDL cholesterol and PCSK9 plasma levels in dyslipidemic cynomolgus monkeys: Effects of LDL lowering by ezetimibe in the absence of statins

Atherosclerosis

Volumn 231, Issue 1, 2013, Pages 84-90

  Hentze, Hannes ^a   Jensen, Kristian K ^b   Chia, Ser Mien ^a   Johns, Douglas G ^b   Shaw, Rachel J ^a   Davis, Harry R ^b   Shih, Shian Jiun ^a   Wong, Kenny K ^b  

^a MSD   (Singapore)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Dyslipidemia; Ezetimibe; Non human primate; PCSK9

Indexed keywords

EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PCSK9 PROTEIN; SUBTILISIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DYSLIPIDEMIA; FOOD; LIPID DIET; LIPID METABOLISM; MACACA FASCICULARIS; NONHUMAN; PRIORITY JOURNAL;

DYSLIPIDEMIA; EZETIMIBE; NON-HUMAN PRIMATE; PCSK9;

ANIMALS; AZETIDINES; CHOLESTEROL, DIETARY; CHOLESTEROL, LDL; DIET, HIGH-FAT; DYSLIPIDEMIAS; MACACA FASCICULARIS; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84885412701     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.08.028     Document Type: Article

References (33)

1. Yin W., Carballo-Jane E., McLaren D.G., et al. Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. JLipid Res 2012, 53:51-65.
2. Brown M.S., Goldstein J.L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997, 89:331-340.
3. Davis H.R., Zhu L.J., Hoos L.M., et al. Niemann-Pick C1 like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. JBiol Chem 2004, 279:33586-33592.
4. Engelking L.J., Kuriyama H., Hammer R.E., et al. Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. JClin Invest 2004, 113:1168-1175.
5. Castro-Perez J., Previs S.F., McLaren D.G., et al. Invivo D2O labeling to quantify static and dynamic changes in cholesterol and cholesterol esters by high resolution LC/MS. JLipid Res 2011, 52:159-169.
6. Gould R.G., Taylor C.B., Hagerman J.S., Warner I., Campbell D.J. Cholesterol metabolism. I. Effect of dietary cholesterol on the synthesis of cholesterol in dog tissue invitro. JBiol Chem 1953, 201:519-528.
7. Turley S.D., Spady D.K., Dietschy J.M. Identification of a metabolic difference accounting for the hyper- and hyporesponder phenotypes of cynomolgus monkey. JLipid Res 1997, 38:1598-1611.
8. Telford D.E., Sutherland B.G., Edwards J.Y., Andrews J.D., Barrett P.H., Huff M.W. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. JLipid Res 2007, 48:699-708.
9. Repa J.J., Turley S.D., Quan G., Dietschy J.M. Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption. JLipid Res 2005, 46:779-789.
10. Horton J.D., Cohen J.C., Hobbs H.H. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 2007, 32:71-77.
11. Dubuc G., Chamberland A., Wassef H., et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arteriosclerosis Thromb Vasc Biol 2004, 24:1454-1459.
12. van Heek M., Compton D.S., Davis H.R. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur J Pharmacol 2001, 415:79-84.
13. Davis H.R., Lowe R.S., Neff D.R. Effects of ezetimibe on atherosclerosis in preclinical models. Atherosclerosis 2011, 215:266-278.
14. Cariou B., Le May C., Costet P. Clinical aspects of PCSK9. Atherosclerosis 2011, 216:258-265.
15. Konrad R.J., Troutt J.S., Cao G. Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids Health Dis 2011, 10:38.
16. Dubuc G., Tremblay M., Pare G., et al. Anew method for measurement of total plasma PCSK9: clinical applications. JLipid Res 2010, 51:140-149.
17. Lakoski S.G., Xu F., Vega G.L., et al. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. JClin Endocrinol Metab 2010, 95:800-809.
18. Okada K., Iwahashi N., Endo T., et al. Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease. Atherosclerosis 2012, 224:454-456.
19. Berthold H.K., Seidah N.G., Benjannet S., Gouni-Berthold I. Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels. PloS One 2013, 8:e60095.
20. Owens A.P., Passam F.H., Antoniak S., et al. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. JClin Invest 2012, 122:558-568.
21. Williams J.K., Sukhova G.K., Herrington D.M., Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. JAm Coll Cardiol 1998, 31:684-691.
22. Ito B.R., Zhang B.H., Cable E.E., et al. Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys. Br J Pharmacol 2009, 156:454-465.
23. Descamps O.S., De Sutter J., Guillaume M., Missault L. Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today?. Atherosclerosis 2011, 217:308-321.
24. Sudhop T., Reber M., Tribble D., et al. Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. JLipid Res 2009, 50:2117-2123.
25. Careskey H.E., Davis R.A., Alborn W.E., Troutt J.S., Cao G., Konrad R.J. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. JLipid Res 2008, 49:394-398.
26. Welder G., Zineh I., Pacanowski M.A., Troutt J.S., Cao G., Konrad R.J. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. JLipid Res 2010, 51:2714-2721.
27. Dong B., Wu M., Li H., et al. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. JLipid Res 2010, 51:1486-1495.
28. Giugliano R.P., Desai N.R., Kohli P., et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012, 380:2007-2017.
29. Koren M.J., Scott R., Kim J.B., et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012, 380:1995-2006.
30. Roth E.M., McKenney J.M., Hanotin C., Asset G., Stein E.A. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. NEngl J Med 2012, 367:1891-1900.
31. Ason B., Tep S., Davis H.R., et al. Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. JLipid Res 2011, 52:679-687.
32. Charlton-Menys V., Durrington P.N. Human cholesterol metabolism and therapeutic molecules. Exp Physiol 2008, 93:27-42.
33. Cariou B., Langhi C., Le Bras M., et al. Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. Nutr Metab 2013, 10:4.